Omega-3 PUFAs prevent bone impairment and bone marrow adiposity in mouse model of obesity

0579053 - FGÚ 2024 RIV GB eng J - Článek v odborném periodiku
Beňová, Andrea - Ferenčáková, Michaela - Bardová, Kristina - Funda, Jiří - Procházka, Jan - Špoutil, František - Čajka, Tomáš - Džubanová, Martina - Balcaen, T. - Kerckhofs, G. - Willekens, W. - van Lenthe, G. H. - Charyyeva, Arzuv - Alquicer, Glenda - Pecinová, Alena - Mráček, Tomáš - Horáková, Olga - Coupeau, Roman - Hansen, M. S. - Rossmeisl, Martin - Kopecký, Jan - Tencerová, Michaela
Omega-3 PUFAs prevent bone impairment and bone marrow adiposity in mouse model of obesity.
Communications Biology. Roč. 6, č. 1 (2023), č. článku 1043. E-ISSN 2399-3642
Grant CEP: GA ČR(CZ) GA20-03586S; GA ČR(CZ) GA19-02411S; GA MŠMT(CZ) LX22NPO5104
Grant ostatní: Novo Nordisk Fonden(DK) NNF20SA0066174
Institucionální podpora: RVO:67985823 ; RVO:68378050
Klíčová slova: bone * mesenchymal stem cells * metabolic bone disease
Obor OECD: Cell biology
Impakt faktor: 5.9, rok: 2022
Způsob publikování: Open access
https://doi.org/10.1038/s42003-023-05407-8

Obesity adversely affects bone and fat metabolism in mice and humans. Omega-3 polyunsaturated fatty acids (omega-3 PUFAs) have been shown to improve glucose metabolism and bone homeostasis in obesity. However, the impact of omega-3 PUFAs on bone marrow adipose tissue (BMAT) and bone marrow stromal cell (BMSC) metabolism has not been intensively studied yet. In the present study we demonstrated that omega-3 PUFA supplementation in high fat diet (HFD + F) improved bone parameters, mechanical properties along with decreased BMAT in obese mice when compared to the HFD group. Primary BMSCs isolated from HFD + F mice showed decreased adipocyte and higher osteoblast differentiation with lower senescent phenotype along with decreased osteoclast formation suggesting improved bone marrow microenvironment promoting bone formation in mice. Thus, our study highlights the beneficial effects of omega-3 PUFA-enriched diet on bone and cellular metabolism and its potential use in the treatment of metabolic bone diseases.
Trvalý link: https://hdl.handle.net/11104/0347932